ADVISORY, Aug. 25, 2014 (GLOBE NEWSWIRE) --
What:
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS ), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, Christopher Cashman, President and Chief Executive Officer of Marinus Pharmaceuticals, Inc. will ring the Opening Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio
When:
Tuesday, August 26, 2014 – 9:15 a.m. to 9:30 a.m. ET
Marinus Pharmaceuticals, Inc. Contact:
Edward Smith
(215) 437-0610
esmith@marinuspharma.com
NASDAQ MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaqomx.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ .
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq .
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx .
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/ .
Webcast:
A webcast of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx .
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS ):
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and has been designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and plans to initiate a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors. For additional information, please visit the Company's website at www.marinuspharma.com .
About NASDAQ OMX Group
NASDAQ OMX (Nasdaq: NDAQ ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com .
-NDAQA-
